Neurosteroids such as allopregnanolone may play a role in epilepsy as positive modulators of inhibitory currents mediated by c-aminobutyric acid type A (GABA A ) receptor. Indeed, these molecules have been consistently shown to be anticonvulsants in animal models, but their role is still unclear in patients. For this reason, we investigated neurosteroids in the cerebrospinal fluid (CSF) of patients with status epilepticus (SE) by liquid chromatography tandem-mass spectrometry. Patients were retrospectively identified within subjects who received a lumbar puncture in the 2007-2017 period. Seventythree patients (median age 65, ranging from 13 to 94 years; 67% women) with SE were evaluated. Controls (n = 52, median age 53, ranging from 16 to 93 years; 65% women) were patients presenting with symptoms for which a lumbar puncture was required by clinical guidelines, and who were negative at the end of the diagnostic work-up. Progesterone was 64% lower in patients with SE (p < 0.001). With respect to progesterone, upstream pregnenolone sulfate and pregnenolone did not change. Instead, downstream 5a-dihydroprogesterone, pregnanolone and allopregnanolone were, respectively, 49% (p < 0.001), 21% (p < 0.01) and 37% (p < 0.001) lower than in controls. Duration or type of SE, age and sex did not consistently affect CSF neurosteroid levels in the SE cohort. Instead, pregnenolone sulfate (Spearman's q = 0.4335, p < 0.01), allopregnanolone (q = 0.4121, p < 0.05) and pregnanolone (q = 0.592, p < 0.001) levels significantly increased by aging in controls. We conclude that neurosteroidogenesis is defective in patients with SE. Keywords: allopregnanolone, cerebrospinal fluid, liquid chromatography-electrospray tandem mass spectrometry (LC-MS/MS), progesterone, status epilepticus, c-aminobutyric acid type A (GABA A ) receptor.
cological treatments. The reason why seizures in SE do not stop spontaneously and may also become unresponsive to drug treatment is currently under investigation. Clinical and experimental evidence suggested that resistance to the effects of benzodiazepines is because of time-dependent changes in the sensitivity of c-aminobutyric acid type A (GABA A ) receptor (Betjemann and Lowenstein 2015) . Decreased inhibition at the synaptic level may occur because of GABA A receptor b2/3 and c2 subunit internalization during SE (Goodkin et al. 2008) . To overcome this phenomenon, stimulation of GABA A extrasynaptic receptors composed by the d subunit could be attained with neurosteroids such as allopregnanolone (Rogawski et al. 2013) . This possibility has been initially supported by evidence of beneficial effects in patients affected by super-refractory SE (SRSE) and treated with allopregnanolone (Broomall et al. 2014; Vaitkevicius et al. 2017) . SRSE represents the most severe form of SE and is characterized by treatment failure with first/second/third-line drugs, including anesthetics (Shorvon and Ferlisi 2011) . Recently, a phase 1/2 trial of neurosteroids in SRSE demonstrated safety and tolerability, but randomized controlled data failed to demonstrate efficacy .
Although neurosteroids could not be proved to efficaciously stop seizures in patients affected by SRSE, they may anyway be relevant for other aspects of SE pathophysiology. We recently found that allopregnanolone and the cognate neurosteroid pregnanolone were present at reduced levels in the cerebrospinal fluid (CSF) of patients affected by SE (Meletti et al. 2017) . This result open the question of whether other neurosteroids, especially those preceding the synthesis of allopregnanolone, could also be altered in patients who experience a SE. This information is required to evaluate if the simple administration of allopregnanolone could be sufficient to restore the central levels of anticonvulsant neurosteroids in presence of SE. Moreover, an even more important question is the possibility that low levels of neurosteroids could represent a possible predisposing factor for SE. In such a case, it could be important to identify the possible metabolic step involved in the reduction.
In this study, we evaluated the overall biosynthetic pathway leading to allopregnanolone. To accomplish our study, we measured the progesterone precursors pregnenolone sulfate and pregnenolone. As progesterone is then metabolized by 5a-reductase type I (Mellon and Griffin 2002) , we measured the intermediate metabolite 5a-dihydroprogesterone. Finally, we evaluated the CSF levels of allopregnanolone, which is produced from 5a-dihydroprogesterone by 3a-hydroxysteroid dehydrogenase, and pregnanolone (Mellon and Griffin 2002) . In performing these studies, we considered a much larger cohort of patients in respect of our previous study (Meletti et al. 2017) .
Materials and methods

Experimental design
We retrospectively considered records of patients admitted with SE between January 2007 and January 2017, who received lumbar puncture at SE onset or during SE. As this study was retrospective, it was not pre-registered.
Definition and inclusion criteria: SE was defined as a continuous seizure or two or more discrete seizures between which there was no complete recovery of consciousness lasting ≥5 min for convulsive SE. In cases of non-convulsive SE, which means an episode of SE not accompanied by prominent motor phenomena or with subtle motor phenomena, a 30 min cut-off was adopted. The most recent proposal for classification of SE is based on 10 min for nonconvulsive SE (Trinka et al. 2015) , but at time when our data were collected this definition was still to be accepted. We included all the episodes in which there was clinical evidence of continue or repetitive seizures or, in cases of non-convulsive SE, those in which the event was classified as SE by the electroencephalography (EEG). The EEG was considered diagnostic for SE when showing: i) ictal or periodic patterns; ii) focal slowing (with or without interictal discharges) unexplained by other causes; iii) generalized slowing with interictal epileptiform activity (in cases ii) and iii), when performed postictally).
CSF samples were extracted (n = 73) from our CSF bank by considering patients for whom the clinical information and EEG were diagnostic for SE. Data were collected by reviewing clinical charts, EEG and the available video-EEG recordings. The treatment protocol for SE was similar in all the patients and followed the guidelines of the Italian League Against Epilepsy (Minicucci et al. 2006) . Response to treatment was evaluated clinically and/or by EEG. A drug trial was considered effective in SE termination if the patient stopped having clinical seizures or, in case of non-convulsive SE, if the EEG recovered to baseline. With respect to treatment outcomes, refractory SE (RSE) was defined as a SE episode that continued, regardless of the delay since the onset of the seizure, after failure of a trial with intravenous benzodiazepines and one or more appropriately chosen AEDs, at adequate dosage (Shorvon and Ferlisi 2011) . This condition often required admission to the Intensive Care Unit and the application of anesthetic drug therapy. SRSE was defined as a SE that continued or recurred after at least 24 h from the beginning of anesthetic therapy or recurred during the reduction or withdrawal of anesthesia (Shorvon and Ferlisi 2011) . Table 1 illustrates the detailed clinical information of our patients according to the new diagnostic and classification proposal of SE by the International League Against Epilepsy (Trinka et al. 2015) . The main CSF characteristics are shown in Table 2 . Seventy-three patients with SE (67% female) with 65 years of median age (ranging from 13 to 94 years) were investigated. CSF samples were taken from few hours after admission up to a maximum of 20 days (median of 2 days) from the SE onset. Considering SE etiology, 26% had a remote symptomatic etiology (previous stroke in 13 patients; post-traumatic gliosis in 6 patients) and, of these patients, eight had a previous diagnosis of epilepsy; 47% of the patients had an acute symptomatic SE episode (cerebrovascular disorder (n = 16), and metabolic disorders (n = 8) were the prominent etiologies in this group); finally, 27% of the cases had a de novo/new onset SE. New onset SE was defined as the SE without a definite etiology in the first 48 h of the diagnostic work-up (Gaspard et al. 2015) . The clinical features of the patients' cohort (few remote etiologies and high incidence of de novo or acute symptomatic causes) were related to the clinical decision of performing a spinal tap early in the diagnostic work-up in the search of infective or autoimmune etiologies. According to the semiology classification, more than half of the group had a non-convulsive SE. Resolution after AEDs occurred in 64% of patients, whereas third-line treatments (anesthetics) were necessary for the others. Overall, mortality within 30 days was 27% (n = 20).
The SE group was compared with patients that underwent a lumbar puncture for other clinical reasons in the same period (n = 52). Sixty-one patients were considered as the non-epileptic control population. Nine patients were excluded from this initial group because of pathological findings in CSF parameters (high intracranial pressure, high cell counts, and positivity for oligo-clonal bands). The final control group consisted of 52 patients with 53 years of median age (range 16-93); 34 were female (65%). The reasons for lumbar puncture were: suspicion of central nervous system (CNS) infection (32 cases), suspected optic neuritis in three, normal pressure hydrocephalus in one, idiopathic intracranial hypertension in 10 and CSF hypotension in six.
The health service (AUSL-Modena) Institutional Review Board approved the research protocol according to local regulations and to the current revision of the Helsinki Declaration. The Ethics Committee assigned to our project the following number: 184/14 (released on 12/3/2014, protocol 4806). Informed written consent was obtained from patients or their relatives.
Quantitative analysis of neurosteroids in CSF by liquid chromatography-electrospray tandem mass spectrometry (LC-MS/ MS)
Chemicals and reagents All neurosteroid standards were purchased from Sigma-AldrichFluka (Milan, Italy). Internal standards with isotope labeling were the following: 5a-pregnan-3a-ol-20-one-17a,21,21,21-d4 (AP-D4; catalog number: D-6894) and sodium pregnenolone-17a,21,21,21-d4 sulfate (PS-D4; catalog number: D-5948), purchased from CDN Isotopes (Pointe-Claire, QC, Canada). All solvents were liquid chromatography-mass spectrometry (LC-MS) purity grade, whereas other solvents used for sample preparation were analytical grade (Sigma-Aldrich-Fluka).
Standard solutions
A stock solution containing all steroids was prepared and serially diluted with methanol to obtain calibration solutions at ten concentration levels. The internal standard solution was prepared apart.
Sample processing
Samples were coded to assure a blind processing and prepared as previously described (Meletti et al. 2017) . Briefly, CSF samples were spiked with internal standard solution, vortexed and added with acetonitrile (catalog number: 900667)/methanol (catalog number: 900688) (70/30; +1.0% formic acid; catalog number: (Trinka et al. 2015). b In patients surviving after SE, n = 53. yrs = years. IRQ = interquartile range. 
LC-MS/MS analysis
LC analyses were performed on a Kinetex XB-C18 column (75 9 2.1 mm; 2.6 lm particle size; catalog number: 00C-4462-AN) preceded by a UHPLC C18 Security Guard cartridge (2.1 mm) (catalog number: AJ0-8782; Phenomenex). Mass spectrometric detection was performed using an Agilent QQQ-MS/MS (6410B) triple quadrupole operating in electrospray positive ionization mode, as described previously (Meletti et al. 2017 ). In the case of progesterone, the presence of two keto groups led to cis/trans derivatives, which eluted as two separable LC peaks; therefore, to quantitate progesterone in CSF samples, the summation of both peaks was used.
Statistics
We calculated the sample size by using the freely available software G*Power (3.0.10; Erdfelder et al. 1996) , by setting an effect size of 0.8, with a power of 0.95 for an a error probability of 0.05. The effect size, estimated for allopregnanolone, was based on our previous study (Meletti et al. 2017 To consider the effects of sex, age, duration and type of SE, data were also analyzed by a general linear model. Then, post hoc Holm-S ıd ak test was used for multiple comparisons. Correlation analysis was performed to evaluate changes in neurosteroid levels as function of the sampling delay from the SE onset. The correlation between neurosteroid levels and SE duration also was considered. The correlation analyses were performed by calculating the respective Spearman's q values and their level of significance. Results are presented as median and interquartile range or mean AE standard error of the mean; they were regarded significant at p < 0.05. (Table 1) , no significant differences were found for sex, whereas controls were younger in respect of patients (p < 0.01, Mann-Whitney U test). Fig. 1 and Table 3 show the results of the quantitative analysis of neurosteroids in CSF by LC-MS/MS in the considered cohorts.
Results
Considering demographic variables
Pregnenolone sulfate and pregnenolone levels were not significantly different in patients with SE and controls (average difference of 10% and 2%, respectively). Major differences were instead found for progesterone (p < 0.001). Specifically, progesterone levels were decreased by 64% in the CSF of patients relative to controls. 5a-Dihydroprogesterone, which follows progesterone and leads to allopregnanolone (Mellon and Griffin 2002) was reduced by 49% (p < 0.001). Consistently with our previous study (Meletti et al. 2017) , allopregnanolone CSF levels were reduced (À37%; p < 0.001) in presence of SE. Finally, also pregnanolone was decreased (À21%, p < 0.01) in the SE cohort.
It has to be noticed that the method used to quantify the different neurosteroids evaluated in the present study was highly effective in detecting pregnenolone sulfate, pregnenolone, progesterone, and 5a-dihydroprogesterone, with only a minority of samples with analyte levels under the detection threshold. In particular, the method was highly performing for progesterone and pregnenolone (0% of samples with analyte level under the detection threshold). In our previous study, instead, a higher percentage of CSF samples (from 20% to 36%) resulted under the detection threshold for allopregnanolone and pregnanolone (Table 3) .
In order to consider the confounding effects of sex, we reanalyzed our data as indicated in Table 4 . For the majority of analytes, within group differences were not found by categorizing subjects by sex. However, 5a-dihydroprogesterone CSF levels were higher in control men compared to women of the same cohort (p < 0.01). We also evaluated the possible effects of age (Fig. 2) . Interestingly, a correlation was found only in controls for pregnenolone sulfate (Spearman's q = 0.4335, p < 0.01), allopregnanolone (q = 0.4121, p < 0.05), and pregnanolone (q = 0.592, p < 0.001), as all of them increased by aging.
Concerning the correlation between time elapsed from the onset of SE (days) to the lumbar puncture, this analysis revealed limited but significant effects of sampling time. In particular, pregnenolone sulfate (q = À0.1921, p < 0.05) and pregnenolone (q = À0.2728, p < 0.05) were negatively correlated with time elapsed from the onset of SE (Fig. 3) . At variance, 5a-dihydroprogesterone was positively correlated with the same variable (q = 0.2962, p < 0.05). However, no significant correlation was found when considering CSF levels of the various analytes and SE duration (days), and no difference emerged also by comparing responsive SE versus RSE/SRSE (data not shown).
Discussion
Neurosteroids can be produced by glial cells and neurons (Miller and Auchus 2011) . Their synthesis is initiated in mitochondria by the cytochrome P450 associated cholesterol (Mellon and Griffin 2002) . The number of available samples was as follows: Pregnenolone, n = 43 for controls, n = 69 for SE; pregnenolone sulfate, n = 47 for controls, n = 68 for SE; progesterone, n = 43 for controls, n = 69 for SE; 5a-dihydroprogesterone, n = 49 for controls, n = 60 for SE; allopregnanolone, n = 36 for controls, n = 47 for SE; pregnanolone, n = 42 for controls, n = 51 for SE. **p < 0.01, ***p < 0.001, Mann-Whitney U test. Abbreviation: HSD, hydroxysteroid dehydrogenase.
side chain cleavage enzyme (P450scc), which is markedly up-regulated in the pilocarpine model of SE (Biagini et al. 2009 ). The neurosteroid produced by cytochrome P450scc, pregnenolone, is then converted to progesterone by 3b-hydroxysteroid dehydrogenase and, after this step, the synthesis of neurosteroids diverges to produce allopregnanolone and pregnanolone (Miller and Auchus 2011) . As pregnenolone and pregnenolone sulfate were at comparable levels in patients affected by SE and controls, whereas progesterone and downstream neurosteroids were all consistently decreased, we hypothesize that 3b-hydroxysteroid dehydrogenase is functionally altered in presence of SE.
In humans, two 3b-hydroxysteroid dehydrogenase isoforms have been identified. Only 3b-hydroxysteroid dehydrogenase isoform 1 is detectable in the brain and its mutation is not compatible with life (Miller and Auchus 2011) . This enzyme is present in both mitochondrial and microsomal fractions and its activity is strongly dependent on NAD + availability, which can be decreased in the course of the SE (Smeland et al. 2013) . Thus, 3b-hydroxysteroid dehydrogenase function might be impaired by reduction in substrate availability in SE. According to this hypothesis, a time-dependent reduction in neurosteroid synthesis is predictable. However, our correlation analysis did not give a convincing support to this hypothesis. Indeed, only a limited decrease in pregnenolone sulfate and pregnenolone CSF levels was observed by delaying time of spinal tap, and no changes were found by analyzing the effect of SE duration, as well as differences in severity of SE.
Another interpretation of our findings is that the reduction in progesterone and the other neurosteroid levels may precede the onset of SE. Subtle, unrecognized changes in steroid synthesis could be caused by mutations in cofactors. For instance, it has been shown that polymorphisms of cytochrome b5 are associated with changes in steroidogenic AP, allopregnanolone; DHP, 5a-dihydroprogesterone; P, pregnenolone; PREG, pregnanolone; PROG, progesterone; PS, pregnenolone sulfate. function (Kok et al. 2010 ) Although this cofactor is known to potently modulate the activity of 3b-hydroxysteroid dehydrogenase (Storbeck et al. 2015) , mutations of cytochrome b5 able to reduce the activity of 3b-hydroxysteroid dehydrogenase are still to be reported. Instead, it has been found that polymorphism of the translocator protein is associated with reduced elevation of corticosteroid levels under adrenocorticotropic hormone stimulation in humans (Owen et al. 2017) , thus suggesting the possibility of impaired steroidogenesis in this condition. However, as translocator protein is an outer mitochondrial membrane protein involved in cholesterol transportation, an impairment of its function should involve the overall process of neurosteroid synthesis, including pregnenolone. Independently of the mechanism, the changes found in the control cohort, showing a small but significant increase in pregnenolone sulfate, allopregnanolone and pregnanolone by aging, which were instead stable in patients with SE, suggest the possibility of a defect in neurosteroid availability preceding the SE. Importantly, allopregnanolone and pregnanolone were not the neurosteroids with the greatest reduction in the presence of SE. Indeed, progesterone and 5a-dihydroprogesterone were those showing the greatest deficiency. This result may Fig. 2 Effects of age on neurosteroid levels. In control group, Spearman correlation was positive for pregnenolone sulfate (Spearman's q = 0.4335, p < 0.01), allopregnanolone (q = 0.4121, p < 0.05), and pregnanolone (q = 0.592, p < 0.001). As regards the other neurosteroids, no significant correlation was found. No significant correlation was found in the status epilepticus cohort. The number of samples was the same indicated in Fig. 1. have relevant clinical implications, especially in relation to the treatment of SE, because it suggests that instead of using allopregnanolone as a possible molecule for SE therapy, progesterone administration might be more rational. Intravenous progesterone formulations are available and have been used in clinical trial for traumatic brain injury (Skolnick et al. 2014) . Intravenous progesterone for critically ill and injured patients has been demonstrated safe and inexpensive (Wigginton et al. 2010) . Recently, a successful treatment of SE in a woman with recurrent SE episodes was also reported (Ramanujam et al. 2016) .
Progesterone, in addition to positively modulate GABA Amediated inhibition, displays genomic regulatory properties and has been shown to display neuroprotective effects (Deutsch et al. 2013) . Based on experimental data, progesterone has been shown to prevent inflammation by inhibiting the production of inflammatory cytokines (e.g., tumor necrosis factor a), as well as by reducing levels of inflammation-related factors and inhibiting the activation of microglial cells. In addition, progesterone has been shown to prevent excitotoxicity and to limit apoptosis by preventing biochemical insults, such as calcium influx and nitric oxide overproduction, and by decreasing levels of caspase 3. Finally, progesterone has also been shown to limit vasogenic edema through reconstitution of the bloodbrain barrier (Drew and Chavis 2000; VanLandingham et al. 2007) .
In spite of the many beneficial properties of progesterone administration found in preclinical studies based on models of epilepsy (Herzog 2015) or nerve tissue injury (Stein 2015) , Phase III clinical trials have been largely discouraging, as in the case of traumatic brain injury (Skolnick et al. 2014; Wright et al. 2014) , because of the lack of significant differences between patients treated with progesterone and controls; or for the limited effects observed in the studied cohort, as in the case of catamenial epilepsy for which the trial revealed significant beneficial effects only for women with perimenstrual seizure exacerbation (Herzog et al. 2012) . In all these studies, however, it was not possible to establish if the increase in peripheral levels of progesterone was followed, and at what extent, by a corresponding increase in CNS of the same (progesterone) or other neurosteroid levels. Indeed, the relationship between peripheral and central levels of neurosteroids is not so clear, as it was not demonstrated for many neurosteroids by studies in rats (Caruso et al. 2013) and not reported in patients affected by multiple sclerosis (Caruso et al. 2014) or post-finasteride syndrome (Melcangi et al. 2017) , or even in our patients with SE (Meletti et al. 2017) .
In conclusion, our study indicates that various neurosteroids able to positively modulate GABA A -mediated inhibition are reduced in the CSF of patients experiencing a SE. These results suggest a diminished regulatory function of GABA in the CNS of these patients. This defect possibly precedes the appearance of seizures. A limitation of our study is that the observed results reflect changes in adults with SE occurring de novo or because of acute CNS disorders. Therefore, more data in different forms of SE are needed. We think that CSF is an important source of biomarkers for epilepsy and SE. For this reason, future multicentric studies are advisable that include also SE episodes in patients with known etiology (remote symptomatic, genetic, etc.).
